Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2024 16:05 ET | Source: CervoMed Inc.

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that...
March 28, 2024 08:30 ET | Source: CervoMed Inc.

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied...
March 05, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed by...
February 21, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the BIO CEO and Investor Conference

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
February 12, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b...
February 07, 2024 08:30 ET | Source: CervoMed Inc.

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating...
February 05, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the Emerging Growth Conference 67

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
January 05, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the Emerging Growth Conference 66

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...